MX2020013831A - Composiciones farmaceuticas en forma liofilizada. - Google Patents

Composiciones farmaceuticas en forma liofilizada.

Info

Publication number
MX2020013831A
MX2020013831A MX2020013831A MX2020013831A MX2020013831A MX 2020013831 A MX2020013831 A MX 2020013831A MX 2020013831 A MX2020013831 A MX 2020013831A MX 2020013831 A MX2020013831 A MX 2020013831A MX 2020013831 A MX2020013831 A MX 2020013831A
Authority
MX
Mexico
Prior art keywords
group
pharmaceutical compositions
disaccharide
lyophilized form
substance selected
Prior art date
Application number
MX2020013831A
Other languages
English (en)
Spanish (es)
Inventor
Oliver Denk
Original Assignee
Breath Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Breath Therapeutics Gmbh filed Critical Breath Therapeutics Gmbh
Publication of MX2020013831A publication Critical patent/MX2020013831A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2020013831A 2018-06-27 2019-06-25 Composiciones farmaceuticas en forma liofilizada. MX2020013831A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18180177 2018-06-27
PCT/EP2019/066875 WO2020002353A1 (en) 2018-06-27 2019-06-25 Pharmaceutical compositions in lyophilized form

Publications (1)

Publication Number Publication Date
MX2020013831A true MX2020013831A (es) 2021-03-25

Family

ID=62814888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013831A MX2020013831A (es) 2018-06-27 2019-06-25 Composiciones farmaceuticas en forma liofilizada.

Country Status (11)

Country Link
US (2) US20210244664A1 (https=)
EP (1) EP3813788A1 (https=)
JP (1) JP7401471B2 (https=)
CN (1) CN113038930A (https=)
AU (1) AU2019295027B2 (https=)
BR (1) BR112020026629A2 (https=)
CO (1) CO2021000223A2 (https=)
EA (1) EA202092893A1 (https=)
IL (1) IL279760B2 (https=)
MX (1) MX2020013831A (https=)
WO (1) WO2020002353A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025204688A1 (ja) * 2024-03-26 2025-10-02 株式会社ダイセル リン脂質膜保護用液体組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857319A (en) * 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
EP0208764A4 (en) 1985-01-11 1987-10-08 Univ California METHOD FOR PRESERVING LIPOSOMES.
US4963362A (en) 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
DE69211691T2 (de) 1991-04-19 1997-01-16 Nexstar Pharmaceuticals Inc., Boulder, Col. Pharmazeutische formulierung und pharmazeutisches verfahren
WO1996040064A1 (en) 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Liposomal cyclosporin formulations as agents for immunosuppression and multiple drug resistant indications
TW497974B (en) * 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
US5958378A (en) * 1996-07-03 1999-09-28 Research Development Foundation High dose liposomal aerosol formulations containing cyclosporin A or budesonide
IT1289938B1 (it) * 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
AU2003237863A1 (en) 2002-05-20 2003-12-12 Research Development Foundation Aerosol drug inhibition of lung metastases
EP1687635A2 (en) * 2003-11-26 2006-08-09 Applera Corporation Ligand-containing micelles and uses thereof
EP1750671B1 (en) * 2004-06-03 2008-10-15 Bracco Research S.A. Liposomal assembly for therapeutic and/or diagnostic use
DE102006051512A1 (de) * 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
CA2631243A1 (en) * 2005-12-08 2007-06-14 Wyeth Liposomal compositions
EP1797895A1 (en) * 2005-12-16 2007-06-20 Pevion Biotech Ltd. An adjuvant system comprising virosomes and liposomes
US20110070294A1 (en) * 2009-09-23 2011-03-24 Javeri Indu Methods for the Administration of Drugs Using Liposomes
US20140127288A1 (en) * 2011-05-17 2014-05-08 Mitsubishi Gas Chemical Company, Inc. Liposome containing pyrroloquinoline quinone and sugar
EP3069711A1 (en) * 2015-03-16 2016-09-21 PARI Pharma GmbH Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection

Also Published As

Publication number Publication date
JP2021528450A (ja) 2021-10-21
US20230301914A1 (en) 2023-09-28
AU2019295027B2 (en) 2024-09-19
CO2021000223A2 (es) 2021-01-18
CN113038930A (zh) 2021-06-25
IL279760B2 (en) 2025-10-01
WO2020002353A1 (en) 2020-01-02
CA3104445A1 (en) 2020-01-02
IL279760A (en) 2021-03-01
AU2019295027A1 (en) 2020-12-24
US20210244664A1 (en) 2021-08-12
IL279760B1 (en) 2025-06-01
BR112020026629A2 (pt) 2021-03-23
JP7401471B2 (ja) 2023-12-19
EP3813788A1 (en) 2021-05-05
EA202092893A1 (ru) 2021-04-19

Similar Documents

Publication Publication Date Title
ECSP23041058A (es) Formulación subcutánea de anticuerpo anti-her2
PE20200513A1 (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso
CL2018003178A1 (es) Composición farmacéutica
MX2022004146A (es) Composición farmacéutica de vector de virus adenoasociado y métodos.
BR112022003021A2 (pt) Modificação de pacotes mensageiros de plantas com lipídeos carregados
Oliveira et al. Doxorubicin has in vivo toxicological effects on ex vivo cultured mesenchymal stem cells
MX2019010318A (es) Composiciones limpiadoras cosmeticas.
EP4360652A3 (en) Adeno-associated virus formulations
CL2019003892A1 (es) Nuevos derivados de azaquinolina.
MX2019010598A (es) Composicion farmaceutica que comprende selexipag.
PH12020550051B1 (en) Glp-1 compositions and uses thereof
AR050127A1 (es) Composicion detergente solida altamente soluble en agua que forma un licor de lavado cristalino cuando se disuelve en agua.
AR071852A1 (es) Formulacion farmaceutica de un anticuerpo frente a ox40l
ECSP066817A (es) Productos de película que tienen propiedades de disgregación controlada
AR100268A1 (es) Formulación líquida que comprende compuesto neutralizante de gm-csf
CL2019001049A1 (es) Vacuna contra parvovirus porcino.
JP2009504805A (ja) 抗炎症活性を有するナノエマルジョン組成物
AR095396A1 (es) Formulaciones de anticuerpo
JP2021521171A5 (https=)
MX2020008096A (es) Peptidos de la cadena b de la relaxina lipidados modificados y su uso terapeutico.
PE20201278A1 (es) Una composicion farmaceutica para la anemia
MX2020013831A (es) Composiciones farmaceuticas en forma liofilizada.
CL2021001587A1 (es) Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf
BR112014030623A2 (pt) composição, combinação e respectivos usos
MX2020008360A (es) Forma cristalina de bictegravir sodico.